



Updated Monthly

April 10, 2024

Prepared for:



---

THE ESSENTIAL GUIDE TO

# Non-Dilutive Government Funding

Published by:



## Questions?

Liz Powell, Esq., MPH

[lpowell@G2Gconsulting.com](mailto:lpowell@G2Gconsulting.com)

[www.G2Gconsulting.com](http://www.G2Gconsulting.com)

  @G2Gconsulting





## TABLE OF CONTENTS

### New Opportunities

Advanced Research Projects Agency for Health .....	2
Aging.....	4
Amyotrophic Lateral Sclerosis .....	4
Autism.....	4
Bioengineering.....	4
Biotechnology and Biomanufacturing.....	5
Bone Marrow Failure .....	5
Cancer .....	5
Cardiovascular and Pulmonary Health.....	7
Central Nervous System .....	7
Cognitive and Brain Health.....	8
Combat Casualty Care.....	10
Communication Disorders.....	10
Complementary and Integrative Health.....	10
Coronavirus .....	10
Diagnostics .....	11
Digital Healthcare .....	11
Disabilities.....	11
Duchenne Muscular Dystrophy.....	12
Endocrine & Metabolic Disease .....	12
Epilepsy.....	13
Genomics .....	13
Health IT & Data.....	13

## GBG Report

Updated Monthly

April 10, 2024

<https://www.g2gconsulting.com/gbg-reporting-service/>

Hearing Restoration.....	14
HIV/AIDS .....	14
Immunology & Infectious Disease .....	16
Mental Health.....	18
Neurofibromatosis.....	18
NIH Common Fund.....	18
Peer Reviewed Medical Research.....	19
Rare Diseases .....	19
Reconstructive Transplant .....	20
Research Support .....	20
Small Business Development .....	20
Substance Use Disorder .....	21
Therapeutics.....	21
Vision Health .....	22
Women's Health.....	22

### Recurring Opportunities

Air Force .....	24
Army.....	25
BARDA .....	26
DARPA .....	26
Defense Threat Reduction Agency .....	27
Department of Energy.....	27
Navy .....	27

<b>GBG Acronyms</b> .....	29
---------------------------	----





## GBG Report

Updated Monthly

April 10, 2024

<https://www.g2gconsulting.com/gbg-reporting-service/>

**April 18, 2024** – Join us for G2G’s Monthly [Non-Dilutive Funding: GBG Reporting Service Webinar](#) at 12-12:30pm EDT (FREE to all) and 12:30-1:00pm EDT (premium service private consultation for G2G and GBG clients). If you’re an affiliate of BioUtah, Bio Nebraska, Focused Ultrasound Foundation, iBIO, Indiana Health Industry Forum, IowaBio, MichBio, NCBiotech, Ohio Life Sciences, South Dakota Biotech, or VaBio – your membership gets you access to the private consultation webinar.

**Women’s Health News:** G2G CEO Liz Powell has co-founded the **Women’s Digital Health Network**. [Learn more](#) and join! The WDHN’s official kickoff event is on May 9 at 12 EDT. [Register here](#).

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (8)</b>		
1.	Personalized Regenerative Immunocompetent Nanotechnology Tissue (PRINT) (ARPA-H)  ARPA-H-SN-24-101	The PRINT program intends to use state-of-the-art bioprinting technology and a regenerative medicine approach to 3D print personalized, on demand organs that do not require immunosuppressive drugs. The goal is to use patient cells or a biobank to quickly produce immune- and blood type-matched replacement organs, such as kidneys, hearts, and lungs. If successful, PRINT technology would decrease donor list wait times, reduce the need and cost for immunosuppressive drugs, and make organs and tissues more widely available for patients across the country. <a href="https://arpa-h.gov/research-and-funding/programs/print">https://arpa-h.gov/research-and-funding/programs/print</a> <a href="https://sam.gov/opp/36d4f3a2fe784a919ca930029833bfd6/view">https://sam.gov/opp/36d4f3a2fe784a919ca930029833bfd6/view</a>	Dependent upon proposal and available funds	Proposers' Day: 5/7/24 Solution Summary: 5/28/24 Invited Proposal: 7/8/24
2.	RFI: Possible Directions in Autonomous Robotic Surgery (ARPA-H)  ARPA-H-SN-24-106	ARPA-H is seeking information on possible directions in autonomous robotic surgery. In autonomous robotic surgery, a robot performs part, or all, of a surgical procedure without direct surgeon input. <a href="https://sam.gov/opp/5e913069746c48038387ceaea7d1186f/view">https://sam.gov/opp/5e913069746c48038387ceaea7d1186f/view</a>	N/A	Response: 4/22/24
3.	Platform Accelerating Rural Access to Distributed & InteGrated Medical care (PARADIGM) (ARPA-H)  ARPA-H-SOL-24-02	PARADIGM will deliver hospital-level care via a multi-purpose Care Delivery Platform (CDP) that is as convenient as telehealth. The CDP will pioneer new developments in point-of-care diagnostics, ensure seamless data exchange between medical devices and electronic health records (EHRs), and offer real-time guidance for medical tasks. <a href="https://sam.gov/opp/87ab5168e45f4037b6dc719e6d557c78/view">https://sam.gov/opp/87ab5168e45f4037b6dc719e6d557c78/view</a>	Dependent upon proposal and available funding	Proposal: 4/26/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH</b>		
4.	Office-Wide Innovative Solutions Opening for Resilient Systems Office (RSO) (ARPA-H)  ARPA-H-SOL-24-103	RSO seeks solution summaries and proposals that drive innovations to enhance the adaptability, reliability, and interoperability of the health ecosystem. The following interest areas categorize the ground-breaking research we seek to support: Sociotechnical System Innovation; Health Ecosystem Integration; and Adaptive & Antifragile Solutions.  <a href="https://sam.gov/opp/76679cd8810f40229694c60c0a593302/view">https://sam.gov/opp/76679cd8810f40229694c60c0a593302/view</a>	Dependent upon proposal and award mechanism	Solution Summaries: 3/3/25 Proposal: 3/15/25
5.	Office-Wide Innovative Solutions Opening for Health Science Futures (HSF) (ARPA-H)  ARPA-H-SOL-24-104	HSF awardees will develop innovative technologies, tools, and platforms that can be applied to a broad range of diseases. The following interest areas define the ground-breaking research we seek to support: Breakthrough Technologies; Transformative Tools; and Platform Systems.  <a href="https://sam.gov/opp/9a301dc812ba47268323e3130e381f19/view">https://sam.gov/opp/9a301dc812ba47268323e3130e381f19/view</a>	Dependent upon proposal and award mechanism	Solution Summaries: 3/3/25 Proposal: 3/15/25
6.	Office-Wide Innovative Solutions Opening for Scalable Solutions Office (SSO) (ARPA-H)  ARPA-H-SOL-24-105	ARPA-H SSO seeks solutions to improve the scalability and affordability of health care solutions, bridge gaps in underserved areas, and extend remote access to expertise by developing location-specific interventions, telemedicine solutions, and mobile health clinics. Solutions should focus on rapid innovation and the use of partnerships, as well as flexible distribution networks and streamlined manufacturing processes. SSO interest areas include: Scalable Technologies and Interventions; Collaborative Distribution Networks; and Biomanufacturing Innovations.  <a href="https://sam.gov/opp/134cdc5d93b34c0ea39498055f315624/view">https://sam.gov/opp/134cdc5d93b34c0ea39498055f315624/view</a>	Dependent upon proposal and award mechanism	Solution Summaries: 3/3/25 Proposal: 3/15/25
7.	Office-Wide Innovative Solutions Opening for Proactive Health Office (PHO) (ARPA-H)  ARPA-H-SOL-24-106	The Proactive Health Office (PHO) at ARPA-H is seeking solutions to improve the healthspan and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Interest areas include: Novel prevention, detection and prophylactic treatment methods for disease; Population-level approaches to increase the adoption of prevention and wellness behaviors; and System innovation for the delivery of proactive health outcomes.  <a href="https://sam.gov/opp/53707a1538994e7d9ed8df8e5ee95ed1/view">https://sam.gov/opp/53707a1538994e7d9ed8df8e5ee95ed1/view</a>	Dependent upon proposal and award mechanism	Solution Summaries: 3/3/25 Proposal: 3/15/25
8.	Forecast: Engineering Of Immune Cells Inside The Body (EMBODY) (ARPA-H)  ARPA-H-SN-24-08	To make immune therapies more affordable, easily accessible at any U.S. hospital, and to eliminate the multi-week wait time, EMBODY will focus on two major technical areas. Technical area 1 encompasses cell-specific delivery methods and development of programmable and controllable genetic material. Technical area 2 supports advanced production and validation methods, including reducing manufacturing cost, improving quality control, and developing predictive preclinical models of the human immune system.  <a href="https://arpa-h.gov/research-and-funding/programs/embody">https://arpa-h.gov/research-and-funding/programs/embody</a>	Dependent upon proposal and award mechanism	Proposers' Day: 4/18/24 Solution Summary: 5/2/24 Proposal: 6/11/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>AGING (2)</b>		
9.	Nathan Shock Centers of Excellence in Basic Biology of Aging and Coordinating Center (P30/U24 Clinical Trial Not Allowed) (NIH/NIA)  RFA-AG-25-012 (P30) RFA-AG-25-013 (U24)	These NOFOs invite applications for NSCs and an NSC3. The Center grants will provide funding for leadership, training, research, and outreach activities that will increase and disseminate scientific knowledge in areas supported by the NIA's Division of Aging Biology (DAB). The goal of the NSC3 is to provide logistical and organization support of the NSCs. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-012.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-012.html</a> (P30) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-013.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-013.html</a> (U24)	Up to \$1.1 million per year, for up to 5 years (P30) Up to \$1 million per year, for up to 5 years (U24)	Letter of intent: 5/15/24 Proposal: 6/14/24 (P30) Letter of intent: 5/15/24 Proposal: 6/15/24 (U24)
		<b>AMYOTROPHIC LATERAL SCLEROSIS (4)</b>		
10.	FY24 Amyotrophic Lateral Sclerosis Research Program (ALSRP) (DoD/CDMRP)  HT942524ALSRRPCTA (CTA) HT942524ALSRPCOBA (COBA) HT942524ALSRRPTDA (TDA) HT942524ALSRRPTIA (TIA)	Four awards are posted: Pilot Clinical Trial Award, Clinical Outcomes and Biomarkers Development Award, Therapeutic Development Award, and Therapeutic Idea Award. FY24 ALSRP Pilot Clinical Trial Award applications must address one of the following Focus Areas: Interventions and Clinical Care. FY24 ALSRP Clinical Outcomes and Biomarkers Award applications must address one or both Focus Areas: Clinical Biomarkers and Clinical Outcomes. <a href="https://cdmrp.health.mil/funding/alsrp">https://cdmrp.health.mil/funding/alsrp</a>	Up to \$2 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 5/24/24 Proposal: 7/10/24
		<b>AUTISM (3)</b>		
11.	FY24 Autism Research Program (ARP) (DoD/CDMRP)  HT942524ARPCDA (CDA) HT942524ARPCTA (CTA) HT942524ARPIDA (IDA)	The ARP supports research of exceptional scientific merit and innovation with high impact that focuses on autism spectrum disorders (ASD). Three awards are included as part of the FY24 ARP: Clinical Trial Award, Idea Development Award, and Career Development Award. <a href="https://cdmrp.health.mil/funding/arp">https://cdmrp.health.mil/funding/arp</a>	Up to \$2.2 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 5/16/24 Proposal: 8/15/24
		<b>BIOENGINEERING (1)</b>		
12.	RPI: Dried Plasma Product System – Seeking New Technologies and Development Partners (MTEC)  24-08-Plasma	This RPI is focused on surveying the current state of engineering and medical prototypes, knowledge products, and manufacturing capacity related to the dried plasma products for use by warfighters. <a href="https://mtec-sc.org/wp-content/uploads/2024/03/24-08-Plasma-RPI.pdf">https://mtec-sc.org/wp-content/uploads/2024/03/24-08-Plasma-RPI.pdf</a>	N/A	Project information paper: 4/25/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>BIOTECHNOLOGY AND BIOMANUFACTURING (4)</b>		
13.	NOSI: Translating Biomaterials-Based Technologies to Commercially Viable Products (NIH)  NOT-EB-24-001	This NOSI invites SBIR and STTR applications focused on advancing paradigm-shifting biomaterials-based technologies leading to commercialized products. Additionally, this NOSI aims to generate private-sector interest and engagement in the development of innovative and emerging biomaterials-based technologies of biomedical and clinical relevance with high commercialization potential.  <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-EB-24-001.html">https://grants.nih.gov/grants/guide/notice-files/NOT-EB-24-001.html</a>	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 4/5/27
		<b>BONE MARROW FAILURE (2)</b>		
14.	Forecast: FY24 Bone Marrow Failure Research Program (DoD/CDMRP)	Two awards are anticipated: Idea Development Award and Investigator-Initiated Research Award. Applications must address one or more of the Focus Areas: Understand the causes and progression of bone marrow failure (BMF) diseases; and find effective BMF treatments and cures.  <a href="https://cdmrp.health.mil/pubs/press/2024/24bmfprpreann">https://cdmrp.health.mil/pubs/press/2024/24bmfprpreann</a>	Up to \$850,000, for up to 3 years Dependent upon proposal and award mechanism	TBD
		<b>CANCER (30)</b>		
15.	Forecast: NCI SBIR Innovative Concept Award Program – Fiscal Year 2025 (NIH/NCI)  75N91024R00013	The NCI is soliciting proposals from SBCs to perform key activities to demonstrate technical feasibility and proof-of-concept for the development of highly innovative and potentially transformative technologies in the following areas: Development of therapeutic or preventative technologies for treatment or prevention of Pediatric Cancers and/or Rare Cancers; and Development of devices, diagnostic technologies, or digital health tools for treatment, detection, and diagnosis of Pediatric Cancers and/or Rare Cancers.  <a href="https://sam.gov/opp/56789d3538e44d668456532c5766c190/view">https://sam.gov/opp/56789d3538e44d668456532c5766c190/view</a>	TBD	Estimated post date: 4/12/24 Estimated proposal date: late September 2024
16.	FY24 Breast Cancer Research Program (BCRP) (DoD/CDMRP)  HT942524BCRPBTA12 (BTA12) HT942524BCRPBTA3 (BTA3) HT942524BCRPBTA4 (BTA4) HT942524BCRPCREA (CREA) HT942524BCRPEOHS (EOHS) HT942524BCRPTBCCDA (TBCCDA) HT942524BCRPTBCCA (TBCCA)	Seven awards are posted: Breakthrough Award Levels 1-2, 3, and 4; Era of Hope Scholar Award; Clinical Research Extension Award; Transformative Breast Cancer Consortium Award; and Transformative Breast Cancer Consortium Development Award. Applications submitted to the FY24 BCRP must address one or more of the <a href="#">overarching challenges</a> .  <a href="https://cdmrp.health.mil/funding/bcrp">https://cdmrp.health.mil/funding/bcrp</a>	Up to \$25 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 5/16/24 Proposal: 5/30/24 (BTA12/TBCCDA) Pre-Application: 5/14/24 Invited proposal: 8/6/24 (BTA3/BTA4/TBCCA) Pre-Application: 5/23/24 Proposal: 6/4/24 (CREA/EOHS)



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>CANCER</b>		
17.	FY24 Lung Cancer Research Program (DoD/CDMRP)  HT942524LCRPCDA (CDA) HT942524LCRPCA (CA) HT942524LCRPIDA (IDA) HT942524LCRPPCOSA (PCOSA) HT942524LCRPTRA (TRA)	The FY24 LCRP posted 5 awards: Concept Award, Career Development Award, Idea Development Award, Translational Research Award, Patient-Centered Outcomes and Survivorship Award. All applications must address one or more <a href="#">Areas of Emphasis</a> . <a href="https://cdmrp.health.mil/funding/lcrp">https://cdmrp.health.mil/funding/lcrp</a>	Up to \$1.2 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 5/28/24 Proposal: 6/17/24 (CDA/CA) Pre-Application: 5/28/24 Proposal: 8/7/24 (IDA/PCOSA/TRA)
18.	FY24 Ovarian Cancer Research Program (DoD/CDMRP)  HT942524OCRPCTA (CTA) HT942524OCRPCTTERA (CTTERA) HT942524OCRPIIRA (IIRA) HT942524OCRPOCAECI (OCAECIA) HT942524OCRPOCALA (OCALA) HT942524OCRPPA (PA)	The OCRP will support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of Service Members, Veterans, their Family members, and all women impacted by this disease. Seven awards are posted: Clinical Trial, Clinical Trial Translational Endpoints, Investigator-Initiated Research, Ovarian Cancer Academy - Leadership, Ovarian Cancer Academy - Early-Career Investigator, Ovarian Cancer Clinical Trial Academy - Early-Career Investigator, and Pilot Award. <a href="https://cdmrp.health.mil/funding/ocrp">https://cdmrp.health.mil/funding/ocrp</a>	Up to \$2 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 5/14/24 Invited proposal: 8/6/24 (IIRA/OCAECIA/PA) Pre-Application: 6/3/24 Proposal: 8/6/24 (CTA/CTTERA/OCALA)
19.	Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Minority Health (CHD-MH) (U54 Clinical Trial Optional) (NIH/NCI)  RFA-CA-24-020	The program will fund a network of multidisciplinary, multi-institutional U54 CHD-MH SPOREs uniquely focused on health disparities and/or minority health translational research for improved prevention, early detection, diagnosis, and treatment of cancer in populations who are underserved (and/or underrepresented). <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-020.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-020.html</a>	Up to \$1.6 million per year, for up to 5 years	Letter of intent: 8/26/24 Proposal: 9/26/24
20.	Forecast: FY24 Peer Reviewed Cancer Research Program (DoD/CDMRP)	Seven awards are anticipated: Advancing Clinical Care Through Clinical Trials Award; Career Development Award – Virtual Cancer Center Scholar Option; Convergent Science Cancer Consortium Award; Idea Award; Impact Award; Patient Well-Being and Survivorship Award; and Virtual Cancer Center Director Award. Applications must address at least one of FY24 PRCRP Topic Areas, and at least one of the Military Health Focus Areas. <a href="https://cdmrp.health.mil/pubs/press/2024/24prcrppreann">https://cdmrp.health.mil/pubs/press/2024/24prcrppreann</a>	Up to \$3 million, for up to 4 years Dependent upon award mechanism	TBD



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>CANCER</b>		
21.	Forecast: FY24 Rare Cancers Research Program (DoD/CDMRP)	Three awards are anticipated: Concept Award, Idea Development Award, Resource and Community Development Award. All applications must address one or more of the appropriate <a href="#">Focus Areas</a> . <a href="https://cdmrp.health.mil/pubs/press/2024/24rcrppreann">https://cdmrp.health.mil/pubs/press/2024/24rcrppreann</a>	Up to \$800,000, for up to 4 years Dependent upon award mechanism	TBD
		<b>CARDIOVASCULAR AND PULMONARY HEALTH (3)</b>		
22.	Forecast: Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional) (NIH/NIDDK)  NOT-DK-24-017	CF Research and Translation Centers support three primary research-related activities: Research Core services; a Pilot and Feasibility program; and an Administrative Core with an enrichment program. These CF Centers provide shared resources to support research to develop and test new therapies for CF and to foster collaborations among institutions with a strong existing research base in CF. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-DK-24-017.html">https://grants.nih.gov/grants/guide/notice-files/NOT-DK-24-017.html</a>	Up to \$750,000 per year	Estimated post date: 4/15/24 Estimated proposal date: 7/17/24
23.	NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required) (NIH/NHLBI)  PAR-24-172	This NOFO supports investigator-initiated, Phase 1 clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be single or multi-site. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-172.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-172.html</a>	Up to \$1.515 million per year, for up to 3 years (R33)	Multiple deadlines; NOFO open through 1/7/27
24.	NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required) (NIH/NHLBI)  PAR-24-173	This NOFO supports investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-173.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-173.html</a>	Up to \$250,000 per year, for up to 2 years (R61) Up to \$1.515 million per year, for up to 3 years (R33)	Multiple deadlines; NOFO open through 1/7/27
		<b>CENTRAL NERVOUS SYSTEM (7)</b>		
25.	FY24 Spinal Cord Injury Research Program (DoD/CDMRP)  HT942524SCIRPCTA (CTA) HT942524SCIRPCTRA (CTRA) HT942524SCIRPTRA (TRA) HT942524SCIRPIIRA (IIRA)	Four awards are posted: Clinical Trial Award; Clinical Translation Research Award; Translational Research Award; Investigator-Initiated Research Award. Applications must address one or more of the <a href="#">Focus Areas</a> . <a href="https://cdmrp.health.mil/funding/scirp">https://cdmrp.health.mil/funding/scirp</a>	Up to \$3.1 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 5/20/24 Proposal: 8/30/24





	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>CENTRAL NERVOUS SYSTEM</b>		
26.	<p>BRAIN Initiative: Recording and Modulation in the Human CNS: Preclinical Proof of Concept, Next-Generation Devices, and Clinical Studies to Advance Next-Generation Devices (UG3/UH3/R18 Clinical Trial Optional/Not Allowed) (NIH)</p> <p>RFA-NS-24-016 (UG3/UH3) RFA-NS-24-017 (UH3) RFA-NS-24-031 (R18)</p>	<p>These NOFOs encourage investigators to pursue translational activities, small clinical studies, first-in-human, early stage clinical studies, and the translation of novel recording and modulation technologies for recording and/or stimulating devices to treat central nervous system disorders and better understand the human brain.</p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-016.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-016.html</a> (UG3/UH3) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-017.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-017.html</a> (UH3) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-031.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-031.html</a> (R18)</p>	<p>Up to \$500,000 per year, for up to 1 year (UG3) Up to \$1.5 million per year, for up to 5 years (UH3) Up to \$750,000 per year, for up to 3 years (R18)</p>	Multiple deadlines; NOFOs open through 1/28/27
		<b>COGNITIVE AND BRAIN HEALTH (10)</b>		
27.	<p>FY24 Peer Reviewed Alzheimer's Research Program (DoD/CDMRP)</p> <p>HT942524PRARPTrCA (TCA) HT942524PRARPTrDA (TDA) HT942524PRARPTrRA (TRA)</p>	<p>Three awards were posted in the PRARP: Transforming Care Award; Transforming Diagnosis Award; and Transforming Research Award. All FY24 PRARP mechanisms have a Career Initiation or Transition Partnering PI Option (CITPO) to encourage research capacity in this critical area.</p> <p><a href="https://cdmrp.health.mil/funding/prarp">https://cdmrp.health.mil/funding/prarp</a></p>	<p>Up to \$2 million, for up to 4 years Dependent upon award mechanism</p>	Pre-Application: 5/22/24 Proposal: 6/20/24
28.	<p>New Approaches for Measuring Brain Changes Across Longer Timespans (R01/R21 Clinical Trial Optional) (NIH)</p> <p>PAR-24-160 (R01) PAR-24-161 (R21)</p>	<p>These NOFOs encourage multidisciplinary investigators to develop new approaches or apply existing approaches in novel ways to measure brain activity, connectivity, genomics, or other aspects across the age spectrum of neurodevelopment.</p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-160.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-160.html</a> (R01) <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-161.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-161.html</a> (R21)</p>	<p>Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)</p>	Multiple deadlines; NOFOs open through 3/16/27
29.	<p>NINDS Program Project Grant (Po1 Clinical Trial Optional) (NIH/NINDS)</p> <p>PAR-24-169</p>	<p>This NOFO encourages grant applications that propose conducting innovative, interactive research to answer significant scientific questions that are important for the mission of NINDS, via a synergistic collaboration between outstanding scientists who might not otherwise collaborate.</p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-169.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-169.html</a></p>	<p>Up to \$1 million per year, for up to 5 years</p>	Multiple deadlines; NOFO open through 1/7/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>COGNITIVE AND BRAIN HEALTH</b>		
30.	Mechanistic and Hemodynamic Basis of Diffuse White Matter Disease in Vascular Contributions to Cognitive Impairment and Dementia (VCID)(R01 - Clinical Trial Not Allowed) (NIH/NINDS/NIA)  PAR-24-196	This NOFO supports hypothesis-testing research to elucidate molecular, cellular and hemodynamic mechanisms that underlie diffuse white matter disease and small vessel disease in the brain and how they may contribute to cognitive decline and dementia. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-196.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-196.html</a>	Up to \$500,000 per year, for up to 5 years	Proposal: 10/4/24
31.	Exploring Proteogenomic Approaches to Unravel the Mechanisms of Mis-Folded Protein Accumulation in Tauopathies (R01 Clinical Trial Not Allowed) (NIH/NIA)  RFA-AG-25-017	This NOFO invites innovative research proposals to explore the accumulation of misprocessed proteins in Tauopathies within specific brain regions and cell types. NIA encourages collaborative efforts to create advanced single-cell or single-cell type proteogenomic platforms. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-017.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-017.html</a>	Up to \$500,000 per year, for up to 5 years	Letter of intent: 5/10/24 Proposal: 6/10/24
32.	Tools and resources to understand the vascular pathophysiology of in vivo neuroimaging findings in ARIA (U24 - Clinical Trials Not Allowed) (NIH/NINDS/NIA)  RFA-NS-24-034	This initiative promotes the development and distribution of innovative technologies, methods, protocols, and biomedical materials that enhance combined human neuropathology and neuroimaging research aimed at understanding the vascular pathogenesis and pathophysiology of anti-A $\beta$ monoclonal antibody (mAb) induced Amyloid Related Imaging Abnormalities (ARIA). <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-034.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-034.html</a>	Up to \$1 million per year, for up to 5 years	Proposal: 5/31/24
33.	Mechanisms of Cognitive Fluctuations in AD/DRD Populations (R01 - Clinical Trial Optional) (NIH/NINDS/NIA)  RFA-NS-25-014	This NOFO invites research applications focused on understanding the underlying pathophysiology of cognitive fluctuations in people diagnosed with AD/DRD. Researchers should propose a clear hypothesis for one or more etiologies that can be measured with standardized assessments that can be collected across multiple time points and/or diagnoses. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-25-014.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-25-014.html</a>	Up to \$825,000 per year, for up to 5 years	Proposal: 6/24/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>COMBAT CASUALTY CARE (1)</b>		
34.	GOLDen hour extended EVACuation (GOLDEVAC) (DoD/DARPA)  HR001124S0024	DARPA is soliciting innovative proposals in the following technical area: intravascular gas-exchange and trauma resuscitation through a single intravascular cannula. Proposed research should investigate innovative approaches that enable revolutionary advances which would develop the necessary device(s) to enable management of a polytrauma patient through a single intravascular access without the thrombotic complications associated with extracorporeal membrane oxygenation. <a href="https://sam.gov/opp/7474001f565c4417bdf7ce02ae741f5f/view">https://sam.gov/opp/7474001f565c4417bdf7ce02ae741f5f/view</a>	Dependent upon proposal and award mechanism	Abstract: 4/24/24 Proposal: 6/4/24
		<b>COMMUNICATION DISORDERS (9)</b>		
35.	NOSI: Development of Imaging Techniques for High Resolution and Functional Scanning of In Vivo Human Sensory and Communication Systems (NIH/NICHD)  NOT-DC-24-025	This NOSI aims to encourage grant applications that propose innovative approaches to developing high-resolution imaging technologies for structures such as the inner ear, olfactory epithelium, taste buds, and vocal production structures during disordered speech. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-DC-24-025.html">https://grants.nih.gov/grants/guide/notice-files/NOT-DC-24-025.html</a>	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI through 5/7/27
		<b>COMPLEMENTARY AND INTEGRATIVE HEALTH (1)</b>		
36.	Botanical Dietary Supplements Translational Research Teams (RM1 Clinical Trial Required) (NIH/ODS/NCCIH/NIDA)  RFA-OD-24-014	This NOFO supports trans-disciplinary, translational research on chemically complex botanical products or natural products traditionally used as dietary components, to inform future clinical trials of the efficacy of exceptionally promising dietary supplements for improving resilience. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-24-014.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-24-014.html</a>	Up to \$1.5 million per year, for up to 5 years	Letter of intent: 6/7/24 Proposal: 7/8/24
		<b>CORONAVIRUS (1)</b>		
37.	Live: Health+ Long COVID Healthathon Innovation Sprint (HHS)	HHS is hosting an innovation sprint—the Long COVID Healthathon—to crowdsource and accelerate digital solutions to support those living with Long COVID today. Participants will share ideas, design, and deliver Long COVID solutions that address the Healthathon challenge question through three tracks. Solutions can come from industry, academic, non-profit or government—all are welcome to join the Long COVID Healthathon! <a href="https://longcovid.crowdicity.com/">https://longcovid.crowdicity.com/</a>	\$25,000 total funds	Proposal: 4/19/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>DIAGNOSTICS (2)</b>		
38.	Development and Application of Ophthalmic Imaging Technologies to Advance Our Understanding of Systemic Diseases (OT2) (NIH Common Fund)  NOT-RM-24-007	This opportunity supports the development and application of novel, noninvasive ocular imaging technologies and machine learning algorithms to identify highly sensitive and specific biomarkers for diseases that affect the entire body. Oculomics can have a significant impact on early detection of diseases before the onset of symptoms, and can help clinicians with early disease intervention, risk assessment, tracking disease progression, and supportive therapeutics. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-RM-24-007.html">https://grants.nih.gov/grants/guide/notice-files/NOT-RM-24-007.html</a>	Up to \$4.8 million per year, for up to 3 years	Letter of intent: 4/16/24 Proposal: 5/27/24
39.	Biothreat Diagnostic Rapid Response (BARDA/RRPV)  RPP-24-06-DxR2	BARDA is seeking to address its product portfolio capability readiness gaps for rapid biothreat diagnostic test development and ready-production capacity to quickly produce tests in lieu of stockpiling. Biothreat tests will be developed and pilot program(s) will be established to assess the feasibility of rapid response capabilities, leveraging existing domestic manufacturing capacities. <a href="https://www.rpv.org/uncategorized/rpp-24-06-dxr2/">https://www.rpv.org/uncategorized/rpp-24-06-dxr2/</a>	Up to \$10 million, for 3 years	Proposal: 5/10/24
		<b>DIGITAL HEALTHCARE (1)</b>		
40.	Forecast: Using Innovative Digital Healthcare Solutions to Improve Quality at the Point of Care (R21/R33 - Clinical Trial Optional) (AHRQ)  NOT-HS-24-011	This NOFO will invite applications that propose research projects that test promising digital healthcare interventions aimed at improving quality of care and healthcare services delivery at the point of care. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-HS-24-011.html">https://grants.nih.gov/grants/guide/notice-files/NOT-HS-24-011.html</a>	TBD	Estimated post date: 7/19/24 Estimated proposal date: 10/16/24
		<b>DISABILITIES (2)</b>		
41.	Disability and Rehabilitation Research Project: Development and Distribution of Mobile Applications For Use By People With Disabilities (HHS/ACL)  HHS-2024-ACL-NIDILRR-DPGE-0084	Applicants must propose to conduct development and knowledge translation activities to facilitate the efficient development and distribution of mobile applications for use by people with disabilities. <a href="https://www.grants.gov/search-results-detail/353298">https://www.grants.gov/search-results-detail/353298</a>	Up to \$600,000 per year, for up to 5 years	Proposal: 6/7/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>DISABILITIES</b>		
42.	Medical Rehabilitation Research Resource (P50 Clinical Trial Optional) (NIH)  RFA-HD-25-001	The Medical Rehabilitation Research Centers will contribute to medical rehabilitation research infrastructure by developing and disseminating techniques, data, theories, research programs, and expertise with the goal of enhancing the capability of medical rehabilitation investigators to understand mechanisms of functional recovery, develop therapeutic strategies, identify clinical care gaps, and improve the lives of people with disabilities. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-25-001.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-25-001.html</a>	Up to \$750,000 per year, for up to 5 years	Letter of intent: 6/30/24 Proposal: 7/30/24
		<b>DUCHENNE MUSCULAR DYSTROPHY (2)</b>		
43.	Forecast: FY24 Duchenne Muscular Dystrophy Research Program (DMDRP) (DoD/CDMRP)	All applications for the FY24 DMDRP Idea Development Award must address opportunities and challenges in the development of safe and effective macromolecular and cellular therapies that focus on the primary pathology of DMD. Two awards are anticipated: Idea Development Award and Clinical/Translational Research Award. <a href="https://cdmrp.health.mil/pubs/press/2024/24dmdrppreann">https://cdmrp.health.mil/pubs/press/2024/24dmdrppreann</a>	Up to \$1.35 million, for up to 3 years Dependent on award mechanism	TBD
		<b>ENDOCRINE &amp; METABOLIC DISEASE (3)</b>		
44.	Discovery of Early Type 1 Diabetes Disease Processes in the Human Pancreas [HIRN Consortium on Beta Cell Death and Survival (CBDS)] (U01 Clinical Trial Not Allowed) (NIH/NIDDK)  RFA-DK-23-007	This NOFO requests applications to explore human pancreatic tissues and the immune compartment for the discovery of specific signaling or processing pathways that may contribute to the asymptomatic phase of T1D, the discovery of early biomarkers of T1D pathogenesis, the development of diagnostic tools for the detection and staging of early T1D in at-risk or recently-diagnosed individuals, and/or the identification and biological validation of therapeutic targets for the development of preventative or early treatment strategies. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-23-007.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-23-007.html</a>	Up to \$550,000 per year, for up to 4 years	Letter of intent: 6/10/24 Proposal: 7/9/24
45.	Adaptation of Diabetes Control Technologies for Older Adults with T1D (R01 Clinical Trial Optional) (NIH/NIDDK)  RFA-DK-24-002	The main objective of this NOFO is to foster development and testing of technologies adaptable to aging-related changes in older adults with T1D to improve diabetes management and quality of life. Older adults may have increased vulnerability to hypoglycemia, cognitive impairment and/or multiple co-morbidities which may affect the risks and benefits of these technologies in this population. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-24-002.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-24-002.html</a>	Up to \$500,000 per year, for up to 5 years	Letter of intent: 6/17/24 Proposal: 7/17/24
46.	Diabetes Research Centers (P30 Clinical Trial Optional) (NIH/NIDDK)  RFA-DK-25-008	This NOFO invites applications for DRCs that are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-008.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-008.html</a>	Up to \$1 million per year, for up to 5 years	Letter of intent: 4/20/24 Proposal: 6/18/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>EPILEPSY (4)</b>		
47.	FY24 Epilepsy Research Program (ERP) (DoD/CDMRP)  HT942524ERPIDA (IDA) HT942524ERPRPA (RPA) HT942524ERPVPТЕРCF (Virtual-P-TERC-F) HT942524ERPLRA (LRA)	Four awards are posted: Idea Development Award, Leveraging Research Award; Research Partnership Award; Virtual Post-Traumatic Epilepsy Research Faculty Award. Applications should address one or more of the Focus Areas: Markers and Mechanisms; Epidemiology; Longitudinal Studies; Innovative Research. <a href="https://cdmrp.health.mil/funding/erp">https://cdmrp.health.mil/funding/erp</a>	Up to \$1.2 million, for up to 3 years Dependent upon award mechanism	Pre-Application: 6/5/24 Proposal: 6/20/24
		<b>GENOMICS (3)</b>		
48.	Forecast: ML/AI Tools to Advance Genomic Translational Research (MAGen) - Development Sites and Coordinating Center (NIH/NHGRI)  NOT-HG-24-029 (DS) NOT-HG-24-030 (CC)	These NOFOs will solicit applications to explore the feasibility of developing AI/ML tools that can enhance the accuracy and precision of predicting how individuals with pathogenic genetic variants manifest disease. The ML/AI tools will leverage existing multimodal genomic and non-genomic data and will be cross validated in genomic translational research settings to ensure the robustness and generalizability of the tools. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-HG-24-029.html">https://grants.nih.gov/grants/guide/notice-files/NOT-HG-24-029.html</a> (DS) <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-HG-24-030.html">https://grants.nih.gov/grants/guide/notice-files/NOT-HG-24-030.html</a> (CC)	Up to \$1.6 million per year, for up to 5 years (UG3)	Estimated post date: 4/26/24 Estimated proposal date: 7/26/24
49.	Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allowed) (NIH Common Fund)  RFA-RM-24-007	This NOFO solicits applications on the optimization and characterization of technologies and assays with the potential for utilization and adoption in regulatory submissions of genome editing therapeutics. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-24-007.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-24-007.html</a>	Dependent upon proposal, for up to 3 years	Letter of intent: 6/26/24 Proposal: 7/26/24
		<b>HEALTH IT &amp; DATA (3)</b>		
50.	Systems Biology Data Platform Leveraging the Accelerating Medicines Partnership (OT2) (NIH Common Fund)  NOT-RM-24-008	Award(s) made through this announcement will support SysBio by providing technical and administrative coordination and support to enable broad use of the data sets and knowledge generated by the different initiatives funded by AMP and, potentially, other complementary data sets. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-RM-24-008.html">https://grants.nih.gov/grants/guide/notice-files/NOT-RM-24-008.html</a>	Up to \$4.8 million per year, for up to 3 years	Proposal: 5/15/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>HEALTH IT &amp; DATA</b>		
51.	BRAIN Initiative: Data Archives for the BRAIN Initiative (R24 Clinical Trial Optional) (NIH)  RFA-MH-25-110	This NOFO solicits applications to develop web-accessible data archives to capture, store, and curate data related to the BRAIN Initiative activities. A goal of this program is to advance research by creating a data archive with appropriate standards and summary information that is broadly available and accessible to the research community for furthering research.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-110.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-110.html</a>	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 6/24/26
52.	Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial Not Allowed) (NIH Common Fund)  RFA-RM-24-006	The purpose of this NOFO is to announce the availability of funding to demonstrate and enhance the utility of selected <a href="#">Common Fund</a> data sets, including generating hypotheses and catalyzing discoveries.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-24-006.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-24-006.html</a>	Up to \$200,000, for up to 1 year	Proposal: 6/27/24
		<b>HEARING RESTORATION (1)</b>		
53.	FY24 Hearing Restoration Research Program (DoD/CDMRP)  HT942524HRRPFRA	The FY24 HRRP includes the Focused Research Award, which has 3 different funding levels. Applications must address one or more of the <a href="#">Focus Areas</a> .  <a href="https://cdmrp.health.mil/funding/hrrp">https://cdmrp.health.mil/funding/hrrp</a>	Up to \$1 million, for up to 3 years Dependent upon award mechanism	Pre-Application: 7/22/24 Proposal: 8/9/24
		<b>HIV/AIDS (11)</b>		
54.	NOSI: Resource-Related Research Project (R24) Applications to Support Collaborative Implementation Science to End the HIV Epidemic (NIH/NIAID)  NOT-AI-24-031	This NOSI seeks applications to the NIAID Resource-Related Research Projects (R24) Notice of Funding Opportunity for one Coordination, Consultation, and Data Management Center (CCDMC) and multiple Regional Consultation Hubs (RCHs) to support the NIH EHE research portfolio. Resource-Related Research Project grants will provide funding for investigator-initiated research projects that will develop resources to serve biomedical research.  <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AI-24-031.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AI-24-031.html</a>	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOSI open through 1/7/25
55.	Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed) (NIH/NIDDK)  PAR-24-162	This NOFO invites applications for innovative basic and translational pilot research projects within the mission of NIDDK that are aligned with NIH HIV/AIDS research priorities.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-162.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-162.html</a>	Up to \$275,000, for up to 2 years	Multiple deadlines; NOFO open through 1/7/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>HIV/AIDS</b>		
56.	Developmental AIDS Research Center (D-ARC) and ARCs on Mental Health and HIV/AIDS (P30 Clinical Trial Optional) (NIH/NIMH)  PAR-24-164 (D-ARC) PAR-24-165 (ARC)	These NOFOs support innovative, interdisciplinary research in several areas, including basic, NeuroHIV, behavioral and social, biostatistics and data science, integrated biobehavioral, applied, clinical, translational, and implementation science.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-164.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-164.html</a> (D-ARC) <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-165.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-165.html</a> (ARC)	Up to \$750,000 per year, for up to 4 years (D-ARC) Up to \$1.5 million per year, for up to 5 years (ARC)	Multiple deadlines; NOFOs open through 8/25/26
57.	Strategies for Controlled Release of HIV Vaccines (SCORE-H) (R01 Clinical Trial Not Allowed) (NIH/NIAID/NIMH)  RFA-AI-24-008	This NOFO supports product-focused research to advance controlled release vaccine strategies to improve immune responses for HIV prevention, treatment, and cure and develop simplified or single-shot vaccination formulations.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-008.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-008.html</a>	Dependent upon proposal, for up to 5 years	Letter of intent: 6/30/24 Proposal: 7/30/24
58.	Tailoring HIV Curative Strategies to the Participant (UM1 Clinical Trial Not Allowed) (NIH/NIAID)  RFA-AI-24-011	This NOFO will support the development of clinical research platforms that will enable future clinical trials to determine whether combinations of HIV cure strategies can be effective when optimally tailored to the participants.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-011.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-011.html</a>	Up to \$2 million, for up to 5 years	Letter of intent: 6/30/24 Proposal: 7/30/24
59.	Cell and Gene Therapies for HIV Cure: Developing a Pipeline (P01 Clinical Trial Not Allowed) (NIH)  RFA-AI-24-013	This NOFO supports multi-project research programs for the development, characterization, and advancement of gene- and cell-based approaches to achieve long-term remission or elimination of HIV.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-013.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-013.html</a>	Up to \$2.2 million per year, for up to 5 years	Letter of intent: 6/30/24 Proposal: 7/30/24
60.	Interaction between ARVs and Hormones in HIV and Coinfections (R01 Clinical Trial Optional) (NIH)  RFA-AI-24-018	This NOFO supports research to identify and characterize the interaction between hormone therapy and antiretroviral drugs (ARVs) used for treatment and prevention of HIV and co-infections.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-018.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-018.html</a>	Dependent upon proposal, for up to 5 years	Letter of intent: 6/30/24 Proposal: 7/30/24





	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>HIV/AIDS</b>		
61.	Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R01/R21 Clinical Trial Not Allowed) (NIH/NIDA)  RFA-DA-25-004 (R01) RFA-DA-25-005 (R21)	These NOFOs support research towards identifying and characterizing neuroimmune networks, communication pathways, and targets that reside within neuroimmune axes, in the context of HIV and substance use. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-004.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-004.html</a> (R01) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-005.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-005.html</a> (R21)	Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	Letter of intent: 10/13/24 Proposal: 10/14/24
62.	Optimizing Health of Children and Adolescents with Perinatal HIV Exposure (U19 Clinical Trial Optional) (NIH)  RFA-HD-25-004	The objective of this NOFO is to generate information needed to develop and to test interventions for the early detection and reduction of long-term effects of in utero/perinatal exposure to antiretroviral therapy (ART) and/or HIV among individuals who are HIV exposed but uninfected (IHEU). <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-25-004.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-25-004.html</a>	Dependent upon proposal, for up to 5 years	Letter of intent: 6/30/24 Proposal: 7/30/24
		<b>IMMUNOLOGY &amp; INFECTIOUS DISEASE (16)</b>		
63.	RFI: Manufacturing Optimization for Filovirus Human Monoclonal Antibodies (BARDA/BioMaP)  75A5012R00003_AVAT_mAb_RFI_SAM	BARDA is interested in advancing manufacturing development for an already identified monoclonal antibody (mAb) cocktail composed of two mAbs. Work will be focused on the development of this antibody cocktail at a CDMO. BARDA anticipates project awards will be made to multiple Contract Development Manufacturing Organization's (CDMOs) with the best solution and capability to manufacture the two antibodies. <a href="https://www.biomap-consortium.org/rfi-filovirus-human-monoclonal-antibodies/">https://www.biomap-consortium.org/rfi-filovirus-human-monoclonal-antibodies/</a>	N/A	Response: 4/20/24
64.	NOSI: Inborn Errors of Immunity/Primary Immunodeficiencies (NIH/NIAID)  NOT-AI-24-024	This NOSI will support research on the discovery and characterization of Inborn Errors of Immunity (IEIs), also referred to as Primary Immunodeficiencies, to understand the causes and mechanisms of disease, enable early detection and molecular diagnosis, and support the development of strategies to treat and eventually cure these disorders. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AI-24-024.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AI-24-024.html</a>	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI through 3/16/27
65.	NOSI: Research to Stimulate Development of Diagnostics, Therapeutics, and Vaccines for Herpes Simplex Virus (HSV) (NIH/NIAID)  NOT-AI-24-028	This NOSI encourages applications which are focused on development of diagnostics, therapeutics, and vaccines for herpes simplex virus (HSV). <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AI-24-028.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AI-24-028.html</a>	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 4/5/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>IMMUNOLOGY &amp; INFECTIOUS DISEASE</b>		
66.	Centers for Research in Emerging Infectious Diseases (CREID) Network and Coordination Center (U01 Clinical Trial Not Allowed) (NIH/NIAID)  RFA-AI-24-006 (RC) RFA-AI-24-016 (CC)	The CREID Network serves to expand knowledge on re-emerging and emerging infectious diseases (re/EIDs) around the globe where outbreaks are most likely to occur while developing expertise, capacity, and readiness to address outbreak-related research. Teams of domestic and international investigators will conduct innovative, collaborative, hypothesis-driven One Health based research, will undertake outbreak-related research when necessary in their geographical areas, and will work across the CREID Network in a coordinated, collaborative, and cooperative fashion.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-006.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-006.html</a> (RC) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-016.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-016.html</a> (CC)	Up to \$850,000 per year, for 5 years (RC) Up to \$1.5 million per year, for 5 years (CC)	Letter of intent: 5/21/24 Proposal: 6/21/24
67.	Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (R01 Clinical Trial Not Allowed) (NIH/NIAID)  RFA-AI-24-010	This NOFO supports the evaluation of early-stage diagnostics and novel diagnostic strategies for Tuberculosis (TB) in the context of existing clinical algorithms in TB endemic countries.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-010.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-010.html</a>	Up to \$3.5 million per year, for 5 years	Letter of intent: 5/28/24 Proposal: 6/28/24
68.	Immunobiology of Xenotransplantation (U01/U19 Clinical Trial Not Allowed) (NIH/NIAID)  RFA-AI-24-019 (U01) RFA-AI-24-020 (U19)	These NOFOs solicit applications to participate in the IXCRP, a multi-center program dedicated to resolving immunologic and physiologic barriers to safe and efficacious xenotransplantation using preclinical pig to nonhuman primate (NHP) or human decedent models of pancreatic islet, kidney, heart, lung, or liver xenotransplantation.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-019.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-019.html</a> (U01) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-020.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-020.html</a> (U19)	Dependent upon proposal, for up to 5 years	Letter of intent: 7/9/24 Proposal: 8/9/24
69.	RFI: Central Influenza Virus and Emerging Infectious Disease Immunogenicity Laboratory Services (BARDA/RRPV)  RFI-24-07-IEID	The objective of this RFI is for BARDA to better refine the requirements for laboratories to provide centralized immunogenicity assay services to support advanced research and development of pandemic influenza virus vaccines and emerging infectious diseases vaccines, including support for Phase 1, 2, and 3 clinical trial endpoints.  <a href="https://www.rpv.org/solicitation/request-for-information/rfi-central_flu_lab/">https://www.rpv.org/solicitation/request-for-information/rfi-central_flu_lab/</a>	N/A	Industry Day: 4/16/24 Response: 4/19/24
70.	Project NextGen: Patch Forward Prize (BARDA)	The Patch Forward Prize, part of Project NextGen, is a \$50 million competition to advance microneedle patch-based RNA vaccines for COVID-19, seasonal influenza, and pandemic influenza. BARDA calls on vaccine developers and patch makers to partner and accelerate new vaccine technologies.  <a href="https://www.patchforwardprize.com/">https://www.patchforwardprize.com/</a>	Up to \$2 million	Proposal: 10/3/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>MENTAL HEALTH (1)</b>		
71.	Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional) (NIH/NIMH)  RFA-MH-25-190	The purpose of this NOFO is to create a pipeline to accelerate the development and early validation of predictive tools and/or biomarkers to inform individual-level treatment selection among two or more existing therapeutics for depression. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-190.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-190.html</a>	Up to \$500,000 per year, for up to 2 years (UG3) Up to \$1.5 million per year, for up to 4 years (UH3)	Letter of intent: 9/18/24 Proposal: 10/18/24
		<b>NEUROFIBROMATOSIS (7)</b>		
72.	Forecast: FY24 Neurofibromatosis Research Program (DoD/CDMRP)	Seven awards are anticipated: Neurofibromatosis Research Academy-Leadership Award, Clinical Trial Award, Early Investigator Research Award, Exploration-Hypothesis Development Award, Investigator-Initiated Research Award, New Investigator Award, and Synergistic Idea Award. All applications must address at least one of the <a href="#">Areas of Emphasis</a> . <a href="https://cdmrp.health.mil/pubs/press/2024/24nfrppreann">https://cdmrp.health.mil/pubs/press/2024/24nfrppreann</a>	Up to \$2 million, for up to 3 years Dependent upon award mechanism	TBD
		<b>NIH COMMON FUND (4)</b>		
73.	NIH Director's Pioneer Award Program (DP1 Clinical Trial Optional) (NIH Common Fund)  RFA-RM-24-002	The NIH Director's Pioneer Award Program supports individual scientists of exceptional creativity who propose bold and highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-24-002.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-24-002.html</a>	Up to \$700,000 per year, for up to 5 years	Proposal: 9/9/24
74.	NIH Director's New Innovator Award Program (DP2 Clinical Trial Optional) (NIH Common Fund)  RFA-RM-24-003	The NIH Director's New Innovator Award Program supports early stage investigators of exceptional creativity who propose bold and highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-24-003.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-24-003.html</a>	Up to \$300,000 per year, for 5 years	Proposal: 8/19/24
75.	NIH Director's Transformative Research Awards (R01 Clinical Trial Optional) (NIH Common Fund)  RFA-RM-24-004	The NIH Director's Transformative Research Award supports individual scientists or groups of scientists proposing bold, groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-24-004.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-24-004.html</a>	Dependent upon proposal, for up to 5 years	Proposal: 9/3/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>NIH COMMON FUND</b>		
76.	NIH Director's Early Independence Awards (DP5 Clinical Trial Optional) (NIH Common Fund)  RFA-RM-24-005	The NIH Director's Early Independence Award supports rigorous and promising investigators who wish to pursue independent research soon after completion of their terminal doctoral degree or post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-24-005.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-24-005.html</a>	Up to \$250,000 per year, for up to 5 years	Proposal: 9/6/24
		<b>PEER REVIEWED MEDICAL RESEARCH (6)</b>		
77.	FY24 Peer Reviewed Medical Research Program (DoD/CDMRP)  HT942524PRMRPCTA (CTA) HT942524PRMRPDA (DA) HT942524PRMRPIIRA (IIRA) HT942524PRMRPIPA (IPA) HT942524PRMRPLBIRA (LBIRA) HT942524PRMRPTTDA (TTDA)	Six awards are posted as Clinical Trial Award; Discovery Award; Investigator-Initiated Research Award; Impact Award; Lifestyle and Behavioral Health Interventions Research Award; and Technology/Therapeutic Development Award. All applications for FY24 PRMRP funding must specifically address one of the <a href="#">FY24 PRMRP Topic Areas</a> and one of the FY24 PRMRP Strategic Goals as it relates to the portfolio-assigned FY24 PRMRP Topic Area.  <a href="https://cdmrp.health.mil/funding/prmrp">https://cdmrp.health.mil/funding/prmrp</a>	Up to \$4 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 5/13/24 Proposal: 8/19/24 (CTA) Pre-Application: 5/6/24 Proposal: 5/23/24 (DA/IIRA) Pre-Application: 5/13/24 Proposal: 6/6/24 (IPA/LBIRA/TTDA)
		<b>RARE DISEASES (2)</b>		
78.	Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional) (NIH)  PAR-24-206	This NOFO invites applications for the Rare Diseases Clinical Research Consortia (RDCRC) that comprise the Rare Diseases Clinical Research Network (RDCRN). The RDCRCs are intended to advance and improve diagnosis, management, and treatment of numerous, diverse rare diseases through highly collaborative, multi-site, patient-centric, translational, and clinical research.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-206.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-206.html</a>	Up to \$1 million per year, for up to 5 years	Letter of intent: 7/13/24 Proposal: 8/13/24
79.	Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed) (NIH/NCATS)  RFA-TR-24-023	This NOFO provides funding to conduct efficacy studies in an established rare disease preclinical model to demonstrate that a proposed therapeutic agent warrants further development. In addition to preclinical efficacy, accompanying pharmacodynamic and pharmacokinetic studies would be supported.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-24-023.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-24-023.html</a>	Up to \$275,000 per year, for up to 2 years	Multiple deadlines; NOFO open through 6/2/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>RECONSTRUCTIVE TRANSPLANT (4)</b>		
80.	Forecast: FY24 Reconstructive Transplant Research Program (RTRP) (DoD/CDMRP)	Four awards are anticipated: Advanced Technology Development Award, Idea Discovery Award, Investigator-Initiated Research Award, and Qualitative Research Validation and Implementation Award. All applications must address at least one of the <a href="#">Focus Areas and sub-bullets</a> . <a href="https://cdmrp.health.mil/pubs/press/2024/24rtrppreann">https://cdmrp.health.mil/pubs/press/2024/24rtrppreann</a>	Up to \$1.5 million, for up to 3 years Dependent upon award mechanism	TBD
		<b>RESEARCH SUPPORT (1)</b>		
81.	Utilizing Equipment to Study Environmental Extrinsic Factors and Enhance Rigor and Reproducibility of Animal Research (R24, Clinical Trials Not-Allowed) (NIH/ORIP)  PAR-24-167	ORIP invites applications to systematically study the roles of critical environmental extrinsic factors in biological, behavioral, and treatment studies using animal model species, with the objective of enhancing the rigor and reproducibility of animal research. The program supports the acquisition or update of modern equipment for measuring, monitoring, recording, and reporting environmental, biological or biobehavioral variables. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-167.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-167.html</a>	Up to \$400,000 per year, for up to 4 years	Multiple deadlines; NOFO open through 9/25/26
		<b>SMALL BUSINESS DEVELOPMENT (5)</b>		
82.	DHA 2024.4 Small Business Innovation Research (SBIR) (DoD/DHA)  DHA244	Direct to Phase II topics are: Sample Collection and Processing Methods to Support Battlefield Wound Infection Diagnostics; Innovative Solutions for Ethylene Oxide Mitigation Used in Sterilization Processes; Advanced Information Technology to Improve Mobility, Interoperability, and Survivability of Expeditionary Medical Command, Control, Communications, and Computers. <a href="https://media.defense.gov/2024/Mar/27/2003421627/-1/-1/0/DHA_SBIR_244_R1.PDF">https://media.defense.gov/2024/Mar/27/2003421627/-1/-1/0/DHA_SBIR_244_R1.PDF</a>	Up to \$3 million, for up to 2 years (Phase II) Dependent upon award mechanism	Proposal: 5/14/24
83.	Forecast: PHS 2024-2 Omnibus Solicitations of the NIH, CDC and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Grant Applications (NIH/CDC/FDA)  NOT-OD-24-087	The Omnibus Solicitations of the NIH, CDC and FDA for SBIR and STTR grant applications are expected to be reissued with new and revised research priorities. The SBIR program is intended to stimulate technological innovation in the private sector; strengthen the role of small business in meeting federal R/R&D needs; increase the commercial application of federally-supported research results; foster and encourage participation by socially and economically disadvantaged SBCs and women-owned business concerns in the SBIR program; and improve the return on investment from federally-funded research for economic and social benefits to the nation. The STTR program is intended to stimulate a partnership of ideas and technologies between innovative SBCs and non-profit research institutions through federally-funded R/R&D. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-OD-24-087.html">https://grants.nih.gov/grants/guide/notice-files/NOT-OD-24-087.html</a>	TBD	Estimated post date: Late Spring 2024 Estimated proposal date: September 2024



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>SUBSTANCE USE DISORDER (3)</b>		
84.	GMP Synthesis of Bulk Drug Testing (NIH/NIDA)  75N95024R00058	NIDA established the medications development program to support, through grants and contracts, every step of the medication's development process: chemical discovery and syntheses; screening; dosage formulation; biochemical, pharmacological, and toxicological testing; and clinical trials to determine safety and efficacy. The purpose for this contract will be to provide a resource for the synthesis of bulk drug substances for use in preclinical toxicity studies as well as clinical safety and efficacy trials.  <a href="https://sam.gov/opp/16e841b77b344f16b72c193499e14893/view">https://sam.gov/opp/16e841b77b344f16b72c193499e14893/view</a>	Up to \$10 million, for up to 5 years	Proposal: 5/3/24
85.	Forecast: Specialized and Comprehensive Alcohol Research Centers (P50/P60 Clinical trial Optional) (NIH/NIAAA)  NOT-AA-24-007 (P50) NOT-AA-24-008 (P60)	These NOFOs will support a broad-based Alcohol Research Centers program to foster and conduct interdisciplinary, collaborative research on Alcohol Use Disorder (AUD), alcohol misuse and alcohol-related problems, and other health-related consequences across the lifespan.  <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AA-24-007.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AA-24-007.html</a> (P50) <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AA-24-008.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AA-24-008.html</a> (P60)	Up to \$1.15 (P50) Up to \$1.25 million (P60)	Estimated post date: 4/15/24 Estimated proposal date: 11/15/24
		<b>THERAPEUTICS (3)</b>		
86.	Forecast: Hermes program BAA (DoD/DARPA)  DARPA-SN-24-55	The Hermes program is explicitly seeking transformative approaches enabling the development of delivery platforms with systemic biodistribution, exceptional endosomal escape efficiency, and minimal toxicity.  <a href="https://sam.gov/opp/ef8ff0ace8f64e4ebcebo4cf10d969f4/view">https://sam.gov/opp/ef8ff0ace8f64e4ebcebo4cf10d969f4/view</a>	TBD	Response: 4/12/24
87.	Partnerships for the Development of Tools to Advance Therapeutic Discovery for Select Antibiotic-Resistant Gram-Negative Bacteria (R01 Clinical Trial Not Allowed) (NIH/NIAID)  RFA-AI-24-021	This NOFO supports milestone-driven projects focused on developing and utilizing novel predictive models, assays, tools, and/or platforms based on penetration and efflux of small molecules to facilitate therapeutic discovery for select Gram-negative bacterial pathogens: <i>carbapenem-resistant Acinetobacter</i> , <i>carbapenem-resistant Enterobacteriales</i> (CRE), and multidrug-resistant <i>Pseudomonas aeruginosa</i> .  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-021.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-021.html</a>	Up to \$750,000 per year, for up to 5 years	Letter of intent: 7/20/24 Proposal: 8/20/24
88.	HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed) (NIH)  RFA-NS-25-012	This NOFO aims to encourage research grant applications for initial translational efforts that will enable a drug discovery program for novel, non-opioid, and non-addictive treatments for pain. The program provides funding to develop and validate assays to support a distinct testing funnel and conduct screening efforts to identify and characterize potential therapeutic agents including small molecules, biologics, and natural products.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-25-012.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-25-012.html</a>	Up to \$350,000 per year, for up to 3 years	Multiple deadlines; NOSI open through 1/15/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>VISION HEALTH (1)</b>		
89.	FY24 Vision Research Program (VRP) (DoD/CDMRP)  HT942524VRPMCRA	The FY24 VRP Mentored Clinical Research Award is posted. Applications submitted to the FY24 VRP must address one or more of the following Focus Areas: Understanding and treatment of eye injury or visual dysfunction as related to military exposure; Diagnosis, stabilization, and treatment of eye injuries in austere environments and prolonged field care settings; or Restoration of visual function after military exposure-related vision loss or severe visual impairment  <a href="https://cdmrp.health.mil/funding/vrp">https://cdmrp.health.mil/funding/vrp</a>	Up to \$75,000, for up to 18 months	Pre-Application: 8/8/24 Proposal: 8/23/24
		<b>WOMEN'S HEALTH (8)</b>		
90.	Enhancing Reviews and Surveillance to Eliminate Maternal Mortality (CDC/NCCDPHP)  CDC-RFA-DP-24-0053	This NOFO aims to improve the overall timeliness and availability of information on strategies for prevention of pregnancy-related deaths and reduction of disparities in pregnancy-related mortality nationally.  <a href="https://www.grants.gov/search-results-detail/349738">https://www.grants.gov/search-results-detail/349738</a>	Dependent upon proposal and available funding	Proposal: 5/20/24
91.	Forecast: The Road to Prevention of Stillbirth (UG1 Clinical Trial Optional/UM2 Clinical Trial Not Allowed) (NIH/NICHD)  NOT-HD-24-009 (UG1) NOT-HD-24-010 (UM2)	The Stillbirth Research Centers will (1) support the development of tools, devices, instrumentation, models, and other technologies that could have a direct clinical or health impact on the incidence of stillbirth; (2) enhance understanding of the mechanisms underlying vulnerability to stillbirth; (3) elucidate abnormalities, structural defects, genetic factors, infections, and/or complications that may contribute to stillbirth and investigation of the fetus, placenta, and maternal tissues; and (4) leverage secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate factors that influence stillbirth risk and related outcomes.  <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-HD-24-009.html">https://grants.nih.gov/grants/guide/notice-files/NOT-HD-24-009.html</a> (UG1) <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-HD-24-010.html">https://grants.nih.gov/grants/guide/notice-files/NOT-HD-24-010.html</a> (UM2)	TBD	Estimated post date: 7/5/24 Estimated proposal date: 11/1/24
92.	Forecast: Advancing Cures and Therapies and ending ENDometriosis diagnostic delays - ACT ENDO (OTA Clinical Trial Optional) (NIH/NICHD)  NOT-HD-24-016	NIH plans to invite applications to develop, advance, and/or validate new devices, biomarkers, and/or methods or repurpose existing devices for non-invasive diagnosis of endometriosis. The ROA will consist of two stages: 1) An open call for pre-applications; and 2) An invitation-only stage to apply in summer of 2024.  <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-HD-24-016.html">https://grants.nih.gov/grants/guide/notice-files/NOT-HD-24-016.html</a>	TBD	TBD



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>WOMEN'S HEALTH</b>		
93.	NOSI: Women's Health Research (NIH)  NOT-OD-24-079	In alignment with the White House Initiative on Women's Health Research, the National Institutes of Health (NIH) is issuing this Notice of Special Interest to highlight interest in receiving research applications focused on diseases and health conditions that predominantly affect women (e.g., autoimmune diseases; depressive disorders, Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD), gender-based-violence), present and progress differently in women (e.g., cardiovascular disease; HIV; reproductive aging and its implications), or are female-specific (e.g., uterine fibroids; endometriosis; menopause).  <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-OD-24-079.html">https://grants.nih.gov/grants/guide/notice-files/NOT-OD-24-079.html</a>	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 11/4/27
94.	DCL: Funding Opportunities for Science and Engineering Research with Impact on Women's Health (NSF)  NSF 24-068	This DCL reaffirms NSF's commitment to fund discovery, innovation, and research translation on topics of relevance to women's health, from the molecular to the ecosystem level, including input from the full range of science, engineering, and education that NSF supports. Pioneering the next generation of discoveries in women's health will require a sustained effort focusing on the socioeconomic impact of women's health, breaking down disciplinary boundaries in carrying out the necessary research to advance understanding of relevant questions, and building a diverse STEM workforce committed to advancing women's health and the health of a citizens.  <a href="https://new.nsf.gov/funding/opportunities/funding-opportunities-science-engineering-research">https://new.nsf.gov/funding/opportunities/funding-opportunities-science-engineering-research</a>	Dependent upon proposal and award mechanism	Dependent upon program







# Recurring Opportunities

April 10, 2024

<https://www.g2gconsulting.com/gbg-reporting-service/>

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>AIR FORCE (3)</b>		
95.	Airman Readiness Medical Research (ARMR) Hybrid BAA  FA8650-20-S-6008	The Warfighter Medical Optimization Division intends to solicit White Papers under this announcement with the focus of conducting medical research in support of optimizing of the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective is dual natured: (1) ensure medical availability of Airmen by analyzing attributes (sensory, behavioral, physiologic) and operational environments (chemical, physical, psychological, biological, radiological stressors) to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to ameliorate these stressors to optimize Airman health and performance.  <a href="https://www.grants.gov/search-results-detail/327332">https://www.grants.gov/search-results-detail/327332</a>	Up to \$49 million, per award	White papers accepted on rolling basis until 5/1/25
96.	Research Interests of the Air Force Office of Scientific Research  FA9550-23-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. These areas are organized and managed in two scientific Departments: Engineering and Information Science (RTA), Physical and Biological Sciences (RTB), and our international offices (EAORD, SOARD, and AOARD).  <a href="https://www.grants.gov/search-results-detail/345653">https://www.grants.gov/search-results-detail/345653</a>	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis
97.	Research Interests of the United States Air Force Academy  USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions.  <a href="https://www.grants.gov/search-results-detail/330175">https://www.grants.gov/search-results-detail/330175</a>	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>ARMY (8)</b>		
98.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB  CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems.  <a href="https://sam.gov/opp/f2d01f5a6c444e32af543e9519a0805f/view">https://sam.gov/opp/f2d01f5a6c444e32af543e9519a0805f/view</a>	Dependent upon proposal	Proposals accepted on a rolling basis through 6/11/27
99.	The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense Broad Other Transaction Authority Announcement (BOTAA)  BOTAA-24-01	JPEO-CBRND is interested in efforts directed toward the development of enabling technologies that speed up the advanced development process. Areas of interest include: Software and Artificial Intelligence (AI), wearable sensors, threat detection, biothreat containment and aeromedical evaluation.  <a href="https://sam.gov/opp/2d04622b25364669857a6a61c576ade9/view">https://sam.gov/opp/2d04622b25364669857a6a61c576ade9/view</a>	Dependent upon proposal	Preproposals accepted through 2/7/29
100.	USAMRDC Broad Agency Announcement for Extramural Medical Research  HT9425-23-S-BAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; Military Operational Medicine; Medical Biological Defense; and Medical Chemical Defense.  <a href="https://www.grants.gov/search-results-detail/343725">https://www.grants.gov/search-results-detail/343725</a>	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/27 Full proposal by invitation
101.	USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development  HT9425-23-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries; PFC; human performance optimization; canine medicine/performance; brain health; immune response; automation of systematic reviews and metanalysis; and novel post-traumatic stress, depression, and anxiety treatment. SOF medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments.  <a href="https://www.grants.gov/search-results-detail/349586">https://www.grants.gov/search-results-detail/349586</a>	Dependent upon proposal	Proposals accepted through 7/31/28 Submission of a pre-proposal is required
102.	Army Research Office Laboratory Broad Agency Announcement for Foundational Research  W911NF-23-S-0001	ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. Topics include Biotronics, Genetics, and Neurophysiology of Cognition; view <a href="#">the full list of research topics</a> .  <a href="https://sam.gov/opp/7560e5d4024b4e94ad3eab6180cfcc36/view">https://sam.gov/opp/7560e5d4024b4e94ad3eab6180cfcc36/view</a>	Dependent upon proposal	Proposals accepted on a rolling basis until 11/20/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>ARMY</b>		
103.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research  W911NF-23-S-0010	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology.  <a href="https://sam.gov/opp/ee8d9eeec4f94269b6e1ac16b09d9417/view">https://sam.gov/opp/ee8d9eeec4f94269b6e1ac16b09d9417/view</a>	Dependent upon proposal	Proposals accepted on a rolling basis until 4/30/28 Full proposal required
104.	Army Applications Lab BAA for Disruptive Applications  W911NF-24-S-0008	AAL is seeking technologies that address a wide range of Army needs consistent with CFT capability focus areas and associated programs and lines of effort as well as potentially disruptive new capabilities that augment or enhance Army capability overmatch.  <a href="https://sam.gov/opp/3f8ec6d36d584ca28364a2f8a10255b7/view">https://sam.gov/opp/3f8ec6d36d584ca28364a2f8a10255b7/view</a>	Dependent upon proposal	Proposals accepted through 4/4/29 Pre-proposal is required
105.	Army Combat Capabilities Development Command Broad Agency Announcement  W911QY20R0022	Broad Agency Announcement Solicitation for the US Army Combat Capabilities Development Command - Soldier Center (CCDC-SC). Please see the BAA solicitation document for the submission instructions and areas of interest.  <a href="https://www.grants.gov/search-results-detail/327285">https://www.grants.gov/search-results-detail/327285</a>	Dependent upon proposal	Proposals accepted on a rolling basis until 2/28/25
		<b>BARDA (2)</b>		
106.	BARDA Broad Agency Announcement  BAA-23-100-SOL-00004	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antimicrobials; Radiological/Nuclear MCMs; Chemical Threat MCMs; Burn and Blast Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics; ImmuneChip+; Flexible and Strategic Therapeutics (FASTx).  <a href="https://sam.gov/opp/764c53aa6dac43538ef902a2bc2af44f/view">https://sam.gov/opp/764c53aa6dac43538ef902a2bc2af44f/view</a>	Dependent upon proposal	Proposal: 9/25/28
107.	BARDA DRIVe EZ-BAA  DRIVeEZBAA22100SOL00003	BARDA is currently accepting submissions through the EZ-BAA for several AOIs: AOI #15: ReDIRECT; AOI #16: Lab at Home; AOI #19: Healing Lungs; AOI #22: ReBoot; AOI #24: RePAIR; AOI #25: FASTx; AOI #27: Stopping Secondary Spread.  <a href="https://sam.gov/opp/acb2fc60fc434f239241bfc63e2e97a6/view">https://sam.gov/opp/acb2fc60fc434f239241bfc63e2e97a6/view</a>	Up to \$750,000 per award	Proposals accepted on a rolling basis Deadlines vary by AOI
		<b>DARPA (2)</b>		
108.	Biological Technologies BAA  HR001123S0045	Research in BTO creates biotechnological capabilities that provide tactical care and restore function to injured warfighters, increase operational resilience, develop novel functional materials, and detect and protect against threats to maintain force readiness.  <a href="https://sam.gov/opp/597bf60984314db1b3ecfce393677c75/view">https://sam.gov/opp/597bf60984314db1b3ecfce393677c75/view</a>	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 6/20/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>DARPA</b>		
109.	Defense Sciences Office, Office-wide  HR001123S0053	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Novel Materials & Structures; Sensing and Measurement; Computation and Processing; Enabling Operations; Collective Intelligence; and Emerging Threats.  <a href="https://sam.gov/opp/972be70efd7e4608b01311466edf6bof/view">https://sam.gov/opp/972be70efd7e4608b01311466edf6bof/view</a>	Dependent upon proposal	Abstracts accepted on a rolling basis until 9/26/24
		<b>DEFENSE THREAT REDUCTION AGENCY (2)</b>		
110.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD)  HDTRA1-14-24-FRCWMD-BAA	DTRA seeks to identify, adopt, and adapt emerging, existing and revolutionary sciences that may demonstrate high payoff potential to Counter-WMD (C-WMD) threats. Current thrust areas include global biosurveillance, biosafety, and biosecurity, and chemical and biological defense.  <a href="https://sam.gov/opp/3b8216acdcc44c46ada2511459918de5/view">https://sam.gov/opp/3b8216acdcc44c46ada2511459918de5/view</a>	Up to \$1 million per year, for up to 5 years	White papers accepted through 9/2024
111.	Research and Development Innovations Broad Agency Announcement  HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across five interrelated thrust areas derived from the <a href="#">2022 DTRA Strategic Plan for RDT&amp;E</a> : <ul style="list-style-type: none"> <li>• Understand current and emerging WMD situations, threats, and capabilities</li> <li>• Enable effective and integrated WMD deterrence</li> <li>• Control, disable, and defeat current and emerging WMD threats</li> <li>• Protect the force and mitigate crises from WMD</li> <li>• Enable cross-cutting capabilities</li> </ul> <a href="https://sam.gov/opp/45f3e82bc46c4d3f89560b700d1123cd/view">https://sam.gov/opp/45f3e82bc46c4d3f89560b700d1123cd/view</a>	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27
		<b>DEPARTMENT OF ENERGY (1)</b>		
112.	FY 2024 Continuation of Solicitation for the Office of Science Financial Assistance Program  DE-FOA-0003177	By integrating genome science with advanced computational and experimental approaches, the Division seeks to gain a predictive understanding of living systems, from microbes and microbial communities to plants and ecosystems. This foundational knowledge enables design and reengineering of microbes and plants underpinning a broad clean energy and bioeconomy portfolio.  <a href="https://www.grants.gov/search-results-detail/350408">https://www.grants.gov/search-results-detail/350408</a>	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/24
		<b>NAVY (3)</b>		
113.	FY24 Broad Agency Announcement for Innovative Environmental Technologies and Methodologies  N3943024S2000	This announcement seeks out technologies and methodologies to reduce environmental impacts from current and past Navy operations, and applies to Navy installations worldwide. NEXWC is interested in environmental technologies and methodologies that are either new, innovative, advance the state-of-the art, or increase knowledge or understanding of a technology or methodology.  <a href="https://sam.gov/opp/2397c9059c3942cfb618400b2d8637e2/view">https://sam.gov/opp/2397c9059c3942cfb618400b2d8637e2/view</a>	Dependent upon proposal	Abstracts accepted on a rolling basis until 4/7/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>NAVY</b>		
114.	Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology  N0001424SB001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. <a href="https://www.nre.navy.mil/work-with-us/funding-opportunities/fy24-long-range-broad-agency-announcement-baa-navy-and-marine">https://www.nre.navy.mil/work-with-us/funding-opportunities/fy24-long-range-broad-agency-announcement-baa-navy-and-marine</a>	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/24
115.	NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research  N00173-24-S-BA01	The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2. <a href="https://sam.gov/opp/1e5fbd8c66d949fdb4cfe0afc8bob76b/view">https://sam.gov/opp/1e5fbd8c66d949fdb4cfe0afc8bob76b/view</a>	Dependent upon proposal and award mechanism	White papers accepted through 12/31/24





### Terms

**AD/ADRD:** Alzheimer's Disease / Alzheimer's Disease Related Dementias

**Aoi:** Area of Interest

**BAA:** Broad Agency Announcement

**BBB:** Blood-Brain Barrier

**CNS:** Central Nervous System

**FOA:** Funding Opportunity Announcement

**IC:** NIH Institutes and Centers

**NOFO:** Notice of Funding Opportunity

**NOSI:** Notice of Special Interest

**PI:** Principal Investigator

**PTSD:** Post-Traumatic Stress Disorder

**RFI:** Request for Information

**RFP:** Request for Proposal

**SBIR:** Small Business Innovation Research

**SDOH:** Social Determinants of Health

**STTR:** Small Business Technology Transfer

**SUD:** Substance Use Disorder

**TRL:** Technology Readiness Level

**VCID:** Vascular Contributions to Cognitive Impairment and Dementia

### Agencies

**ARPA-H:** Advanced Research Projects Agency for Health

**ASPR:** Administration for Strategic Preparedness and Response

**BARDA:** Biomedical Advanced Research and Development Authority

**CDC:** Centers for Disease Control and Prevention

**CDMRP:** Congressionally Directed Medical Research Programs

**DARPA:** Defense Advanced Research Projects Agency

**DHA:** Defense Health Agency

**DoD:** Department of Defense

**FDA:** U.S. Food and Drug Administration

**MTEC:** Medical Technology Enterprise Consortium

**NIH:** National Institutes of Health

[Back to Table of Contents](#)

## GBG Acronyms

*Updated Monthly*

April 10, 2024

<https://www.g2gconsulting.com/gbg-reporting-service/>

**NSF:** National Science Foundation

**PCORI:** Patient-Centered Outcomes Research Institute

**USAMRDC:** U.S. Army Medical Research and Development Command

**USAMRIID:** U.S. Army Medical Research Institute of Infectious Diseases

**USSOCOM:** United States Special Operations Command

### NIH Institutes and Centers

**CC:** NIH Clinical Center

**CIT:** NIH Center for Information Technology

**CSR:** NIH Center for Scientific Review

**FIC:** Fogarty International Center

**NCATS:** National Center for Advancing Translational Sciences

**NCCIH:** National Center for Complementary and Integrative Health

**NCI:** National Cancer Institute

**NEI:** National Eye Institute

**NHGRI:** National Human Genome Research Institute

**NHLBI:** National Heart, Lung, and Blood Institute

**NIA:** National Institute on Aging

**NIAAA:** National Institute on Alcohol Abuse and Alcoholism

**NIAID:** National Institute of Allergy and Infectious Diseases

**NIAMS:** National Institute of Arthritis & Musculoskeletal & Skin Diseases

**NIBIB:** National Institute of Biomedical Imaging and Bioengineering

**NICHD:** Eunice Kennedy Shriver National Institute of Child Health and Human Development

**NIDA:** National Institute on Drug Abuse

**NIDCD:** National Institute on Deafness and Other Communication Disorders

**NIDCR:** National Institute of Dental and Craniofacial Research

**NIDDK:** National Institute of Diabetes and Digestive and Kidney Diseases

**NIEHS:** National Institute of Environmental Health Sciences

**NIGMS:** National Institute of General Medical Sciences

**NIMH:** National Institute of Mental Health

**NIMHD:** National Institute on Minority Health and Health Disparities

**NINDS:** National Institute of Neurological Disorders and Stroke

**NINR:** National Institute of Nursing Research

**NLM:** National Library of Medicine

